JP2020516590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516590A5 JP2020516590A5 JP2019553212A JP2019553212A JP2020516590A5 JP 2020516590 A5 JP2020516590 A5 JP 2020516590A5 JP 2019553212 A JP2019553212 A JP 2019553212A JP 2019553212 A JP2019553212 A JP 2019553212A JP 2020516590 A5 JP2020516590 A5 JP 2020516590A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- oncolytic virus
- virus
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022136745A JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
| JP2024006788A JP2024028541A (ja) | 2017-04-14 | 2024-01-19 | 膀胱癌の治療方法 |
| JP2026000350A JP2026042875A (ja) | 2017-04-14 | 2026-01-05 | 膀胱癌の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485805P | 2017-04-14 | 2017-04-14 | |
| US62/485,805 | 2017-04-14 | ||
| US201762500729P | 2017-05-03 | 2017-05-03 | |
| US62/500,729 | 2017-05-03 | ||
| PCT/US2018/027549 WO2018191654A1 (en) | 2017-04-14 | 2018-04-13 | Methods of treating bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022136745A Division JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516590A JP2020516590A (ja) | 2020-06-11 |
| JP2020516590A5 true JP2020516590A5 (https=) | 2021-06-17 |
Family
ID=63792825
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553212A Pending JP2020516590A (ja) | 2017-04-14 | 2018-04-13 | 膀胱癌の治療方法 |
| JP2022136745A Active JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
| JP2024006788A Pending JP2024028541A (ja) | 2017-04-14 | 2024-01-19 | 膀胱癌の治療方法 |
| JP2026000350A Pending JP2026042875A (ja) | 2017-04-14 | 2026-01-05 | 膀胱癌の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022136745A Active JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
| JP2024006788A Pending JP2024028541A (ja) | 2017-04-14 | 2024-01-19 | 膀胱癌の治療方法 |
| JP2026000350A Pending JP2026042875A (ja) | 2017-04-14 | 2026-01-05 | 膀胱癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11338003B2 (https=) |
| EP (2) | EP4599893A3 (https=) |
| JP (4) | JP2020516590A (https=) |
| KR (1) | KR102949236B1 (https=) |
| CN (1) | CN110573624A (https=) |
| AU (1) | AU2018251987B2 (https=) |
| ES (1) | ES3030923T3 (https=) |
| PL (1) | PL3610026T3 (https=) |
| WO (1) | WO2018191654A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| CN111542601A (zh) * | 2017-11-08 | 2020-08-14 | 国立大学法人鹿儿岛大学 | 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗) |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| US20200222477A1 (en) * | 2019-01-10 | 2020-07-16 | Trizell Ltd. | Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| JP2022524951A (ja) | 2019-02-27 | 2022-05-11 | アクティム・セラピューティクス・インコーポレイテッド | 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌 |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| IL300447A (en) | 2020-08-12 | 2023-04-01 | Actym Therapeutics Inc | Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| WO2025251009A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent |
| WO2025251003A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods of treating bladder cancer using an oncolytic virus |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4590071A (en) | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US7001764B2 (en) | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6432700B1 (en) | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| EP1007715A2 (en) | 1997-03-03 | 2000-06-14 | Calydon, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| AU2003252891B2 (en) | 1998-09-10 | 2006-06-01 | Cold Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| WO2001073093A2 (en) | 2000-03-24 | 2001-10-04 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| EP1320599A2 (en) | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7459154B2 (en) | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US20050282280A1 (en) | 2003-08-28 | 2005-12-22 | Ennist David L | Oncolytic adenoviral vectors encoding GM-CSF |
| AU2003265873A1 (en) | 2003-08-28 | 2005-04-14 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| TW200607859A (en) | 2004-08-23 | 2006-03-01 | Cell Genesys Inc | Oncolytic adenoviral vectors encoding GM-CSF |
| US20060062764A1 (en) | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
| DK1877090T3 (da) | 2005-05-06 | 2014-04-14 | Providence Health System | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| EP2010216A4 (en) | 2006-03-24 | 2010-06-09 | Donald L Morton | MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT |
| WO2007123737A2 (en) | 2006-03-30 | 2007-11-01 | University Of California | Methods and compositions for localized secretion of anti-ctla-4 antibodies |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| AU2009332883B2 (en) | 2008-12-22 | 2015-05-21 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| US20130243731A1 (en) | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| US9056133B2 (en) | 2011-05-25 | 2015-06-16 | Cti-S.A. | Pharmaceutical kit and method for treating cancer |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AU2013296919A1 (en) | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| DK2986311T3 (en) | 2013-04-18 | 2019-02-25 | Tilt Biotherapeutics Oy | IMPROVED ADOPTIVE CELL THERAPY |
| CN106029889A (zh) | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| CN107580501A (zh) * | 2015-03-12 | 2018-01-12 | 维文蒂亚生物公司 | 用于靶向epcam阳性膀胱癌的给药策略 |
| ES2994611T3 (en) | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
-
2018
- 2018-04-13 EP EP25171388.9A patent/EP4599893A3/en active Pending
- 2018-04-13 CN CN201880025068.1A patent/CN110573624A/zh active Pending
- 2018-04-13 ES ES18784592T patent/ES3030923T3/es active Active
- 2018-04-13 KR KR1020197033495A patent/KR102949236B1/ko active Active
- 2018-04-13 EP EP18784592.0A patent/EP3610026B1/en active Active
- 2018-04-13 JP JP2019553212A patent/JP2020516590A/ja active Pending
- 2018-04-13 AU AU2018251987A patent/AU2018251987B2/en active Active
- 2018-04-13 PL PL18784592.0T patent/PL3610026T3/pl unknown
- 2018-04-13 WO PCT/US2018/027549 patent/WO2018191654A1/en not_active Ceased
- 2018-04-13 US US16/605,066 patent/US11338003B2/en active Active
-
2022
- 2022-04-05 US US17/713,975 patent/US12370229B2/en active Active
- 2022-06-16 US US17/842,406 patent/US11596660B2/en active Active
- 2022-08-30 JP JP2022136745A patent/JP7597384B2/ja active Active
-
2024
- 2024-01-19 JP JP2024006788A patent/JP2024028541A/ja active Pending
-
2025
- 2025-06-10 US US19/233,891 patent/US20260014218A1/en active Pending
-
2026
- 2026-01-05 JP JP2026000350A patent/JP2026042875A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516590A5 (https=) | ||
| KR100379569B1 (ko) | 개기원의아데노바이러스벡터및유전자치료에서이의사용방법 | |
| JP2019507761A5 (https=) | ||
| US20130345295A1 (en) | Targeted oncolytic adenovirus for treatment of human tumors, constrcution method and application thereof | |
| Yuan et al. | Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically | |
| JP7144915B2 (ja) | 腫瘍を治療するためのウイルス | |
| CN110741081A (zh) | 肿瘤选择性tata盒和caat盒突变体 | |
| JP2020533411A5 (https=) | ||
| CN102796709A (zh) | 肝癌特异性基因-病毒及其应用 | |
| JP7336791B2 (ja) | 腫瘍を治療するためのコクサッキーウイルスｂ群 | |
| EP4717766A1 (en) | Dendritic cell-targeted viroid dvlp, and preparation method therefor and use thereof | |
| CN109568350B (zh) | 一种用于治疗肿瘤的柯萨奇病毒 | |
| WO2019091457A1 (zh) | 肝脏特异性转录调控序列及其应用 | |
| WO2020233102A1 (zh) | 一种治疗肿瘤或癌症的药物组合物和其应用 | |
| US11951141B2 (en) | Replication-enhanced oncolytic adenoviruses | |
| CN101643750B (zh) | 靶向性溶肿瘤腺病毒载体Ad-TD-gene的构建方法及应用 | |
| JP2024515290A (ja) | 癌治療用アデノウイルス | |
| CN115747174B (zh) | 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用 | |
| CN108685905A (zh) | 维生素c在增强溶瘤腺病毒杀伤肿瘤细胞能力中的应用 | |
| Garcia-Aragoncillo et al. | Design of virotherapy for effective tumor treatment | |
| CN115948411A (zh) | 竞争性表达的il-12和il-23及其基因、重组载体和在制备治疗肿瘤药物中的应用 | |
| CA3070628C (en) | Enterovirus d68 (ev-d68) for treatment of tumor | |
| CN115806944A (zh) | 重组溶瘤病毒rVSVM51R-S在乙肝性肝癌中的应用 | |
| CN116179602A (zh) | 一种sinv感染性载体及其在制备抗肿瘤药物中的应用 | |
| CN116590242A (zh) | 一种重组溶瘤腺病毒及其应用 |